Bristol-Myers Squibb and AstraZeneca expand diabetes alliance
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) announced that Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or an aggregate purchase price of approximately $5.3 billion.
FDA grants priority review to the new drug application for Bayer's Regorafenib
- Details
- Category: Bayer
Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the New Drug Application (NDA) filed end of April 2012 for the oral multi-kinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
Roche to streamline research and development activities
- Details
- Category: Roche
Roche site in Nutley (New Jersey, USA) to be closed - respective R&D activities to be consolidated in Switzerland and Germany. The planned site consolidation and the streamlining of research activities within Roche's Pharma Research and Early Development unit to support efficient allocation of resources for the Group's expanding product development pipeline.
People with HER2-positive metastatic breast cancer lived longer with Roche's Perjeta
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that people with HER-2 positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of PerjetaTM (pertuzumab), Herceptin® (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone in the Phase III CLEOPATRA study.
Bristol-Myers Squibb and Emory University announce partnership
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Emory University announced the formation of a strategic partnership to conduct clinical trials involving Bristol-Myers Squibb's investigational compounds.
AstraZeneca completes acquisition of Ardea Biosciences
- Details
- Category: AstraZeneca
AstraZeneca today announced that on Tuesday 19 June 2012 it completed its acquisition of San Diego, California-based biotechnology company Ardea Biosciences, Inc. The merger was approved by Ardea's stockholders.
Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and the Joslin Diabetes Center, a teaching and research affiliate of Harvard Medical School, announced a new collaboration to promote the development of new medicines for the treatment of diabetes and related disorders. The collaboration was unveiled at the 2012 Bio International Convention in Boston, Mass.
More Pharma News ...
- Takeda's exclusive distribution of Pfizer products in Japan
- Roche employees in 52 countries walk to raise funds to support vulnerable children worldwide
- FDA approves Perjeta (pertuzumab) for people with HER2-positive metastatic breast cancer
- JDRF and Novo Nordisk establish R&D collaboration in type 1 diabetes
- Lilly expands strategic partnership with Chinese manufacturer Novast
- Novartis drug Gilenya® shows long-term efficacy and safety
- Bristol-Myers Squibb Foundation announces $6 million in grants